



The 18th Annual
**Sickle Cell &
 Thalassaemia
 Conference**

IMPROVING THE LIVES OF PEOPLE LIVING WITH SICKLE CELL DISEASE & THALASSAEMIA

2023
25-28
OCTOBER | **County Hall**
Belvedere Road
London SE1 7PB

Day
02 **27TH OCTOBER 2023**
 Welcome To ASCAT

08.00 – 09.00

MEET THE EXPERT – SESSIONS WITH BREAKFAST

Acute Chest Syndrome in Sickle Cell Disease – *Miguel Abboud*

Stroke Screening – *Soundrie Padayachee & Baba Inusa*

PhenX Toolkit for Sickle Cell Research: A Focus on the Social Determinants of Health Collection – *Marsha Treadwell*

Infectious Disease in Sickle Cell Disease – *Stephen Obaro*

The Role of Complement in Sickle Cell Disease – *Pablo Bartolucci*

09.00 – 10.30

SESSION ONE: Chair: *Rachel Kesse-Adu*

Pain Management, Addiction and Dependence

GSTT Experience of Managing Complex and Chronic Sickle Pain via a virtual MDT clinic
(15 mins)

St Georges Model of Managing Complex and Chronic Sickle Pain *(15 mins)*

Optimising Pain Management Approaches a Pain Specialists Perspective, it is not all opiates
(15 mins)

Opioids in Perspective: The Original Indication and Addiction Systems in the UK *(15 mins)*

P-Selectin & Pain *(15 mins)*

Session Discussion, Questions & Answers *(15 mins)*

Karen Sanderson, Elizabeth Rhodes, Rebecca McLoughlin, Fauzia Hasnie, Mike Kelleher and Kenneth Ataga

09.15 – 12.15

EUROBLOODNET: CLOSED SESSION UNDER INVITATION*

Workshop on application of Artificial Intelligence for SCD. What is Artificial Intelligence and how is it used for SCD?



10.30 – 10.45

COMFORT BREAK

10.45 – 11.30

NEW SESSION

To be confirmed



The 18th Annual
**Sickle Cell &
 Thalassaemia
 Conference**

IMPROVING THE LIVES OF PEOPLE LIVING WITH SICKLE CELL DISEASE & THALASSAEMIA

**25-28
 OCTOBER** | **County Hall
 Belvedere Road
 London SE1 7PB**

Day 02

27TH OCTOBER 2023

Continued

11.30 – 12.15

SESSION TWO: Chairs: **Raffaella Collombatti and Crawford Strunk**

Ageing in Sickle Cell Disease

Transition from Paediatric to Adult in Sickle Cell Disease (15 mins)

Organ Complications with Age in Sickle Cell Disease (15 mins)

Session Discussion, Questions & Answers (15 mins)

Mariane De Montalembert and Pablo Bartolucci

12.30 – 13.30

NETWORKING LUNCH OR SPONSORED LUNCH SESSION - HCPs only

Private Lunch Symposium: Vertex Pharmaceuticals

A roundtable discussion: treatment decision perspectives for patients with haemoglobinopathies

13.30 – 14.15

SESSION THREE: Chairs: **Subarna Chakravorty and Lewis Hsu**

Top Selected Abstract Presentations

Utilising Digital, Longitudinal Tracking Of Wearable Metrics And Patient-Reported Outcomes To Predict Vaso-Occlusive Crises In Sickle Cell Disease (10 mins)

Treatment Of Sickle Cell Disease With Voxelotor Through The UK Early Access To Medicines Scheme (10 mins)

Rise Up Campaign: Raising The Bar On Patient Involvement In Clinical Development (10 mins)

ASCAT Committee Panel Questions & Answers (15 mins)

Kim Summers, Perla Eleftheriou and Holly John

14.15 – 14.30

COMFORT BREAK



The 18th Annual
**Sickle Cell &
Thalassaemia
Conference**

IMPROVING THE LIVES OF PEOPLE LIVING WITH SICKLE CELL DISEASE & THALASSAEMIA

**25-28
OCTOBER** | **County Hall
Belvedere Road
London SE1 7PB**

Day
02 **27TH OCTOBER 2023**
Continued

14.30 – 16.15

SESSION FOUR: Chairs: Maria Capellini and Ali Taher

Bone Marrow Transplantation and Gene Therapy

Organ Complications with Age in Thalassaemia (15 mins)

Gene Therapy for Thalassaemia (15 mins)

Affordable Bone Marrow Transplantation for Sickle Cell and Thalassaemia (15 mins)

Session Discussion, Questions & Answers (10 mins)

Break

Access to Gene Therapy for Rare Disease (15 mins)

Transfusion Independence After Exagamglogene Autotemcel In Patients With Transfusion-Dependent B-Thalassaemia (10 mins)

Session Discussion, Questions & Answers (10 mins)

Irene Motta, Sujit Sheth, Lawrence Faulkner, Claire Booth and Ben Carpenter

16.15 – 18.00

POSTER WALK AND POSTER VIEWING: Chair: Wale Atoyebi

19.00 – 23.00

ASCAT CHARITY GALA NIGHT

*Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

This project is carried out within the framework of European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet)-Project ID No 101085717. ERN-EuroBloodNet is partly co-funded by the European Union within the framework of the Fourth EU Health Programme.